Viro - viro - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus süstlis - 50mg 1ml 0.25ml 6tk; 50mg 1ml 0.6ml 12tk; 50mg 1ml 0.45ml 24tk; 50mg 1ml 0.15ml 10tk; 50mg 1ml 0.3ml 1tk; 50mg 1ml 0.2ml 5tk; 50mg 1ml 0.2ml 12tk; 50mg 1ml 0.4ml 24tk; 50mg 1ml 0.5ml 5tk; 50mg 1ml 0.4ml 10tk; 50mg 1ml 0.2ml 6tk; 50mg 1ml 0.3ml 11tk; 50mg 1ml 0.15ml 24tk; 50mg 1ml 0.3ml 24tk; 50mg 1ml 0.6ml 4tk; 50mg 1ml 0.55ml 12tk; 50mg 1ml 0.5ml 1tk; 50mg 1ml 0.4ml 4tk; 50mg 1ml 0.5ml 12tk; 50mg 1ml 0.5ml 10tk; 50mg 1ml 0.25ml 4tk; 50mg 1ml 0.5ml 6tk; 50mg 1ml 0.55ml 4tk; 50mg 1ml 0.45ml 4tk; 50mg 1ml 0.6ml 1tk; 50mg 1ml 0.55ml 24tk; 50mg 1ml 0.4ml 5tk; 50mg 1ml 0.55ml 1tk; 50mg 1ml 0.25ml 10tk; 50mg 1ml 0.2ml 10tk; 50mg 1ml 0.45ml 1tk; 50mg 1ml 0.45ml 5tk; 50mg 1ml 0.5ml 24tk; 50mg 1ml 0.25ml 11tk; 50mg 1ml 0.45ml 10tk; 50mg 1ml 0.5ml 4tk; 50mg 1ml 0.25ml 5tk; 50mg 1ml 0.55ml 10tk; 50mg 1ml 0.45ml 12tk; 50mg 1ml 0.15ml 12tk; 50mg 1ml 0.25ml 24tk; 50mg 1ml 0.35ml 6tk; 50mg 1ml 0.4ml 11tk; 50mg 1ml 0.45ml 6tk; 50mg 1ml 0.35ml 10tk; 50mg 1ml 0.2ml 24tk; 50mg 1ml 0.2ml 1tk; 50mg 1ml 0.3ml 6tk; 50mg 1ml 0.6ml 5

Euroopan unioni - viro - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren, hydrochlorothiazide - hüpertensioon - reniini-angiotensiini süsteemi toimivad ained - essentsiaalse hüpertensiooni ravi täiskasvanutel. riprazo hct on näidustatud patsientidele, kelle vererõhk ei ole adekvaatselt kontrollitav kohta aliskiren või hydrochlorothiazide kasutada üksi. rirpozo hct on näidustatud asendusravi patsiendid piisavalt kontrollitud aliskiren ja hydrochlorothiazide, arvestades samal ajal, samal annus nagu kombinatsioon.

Euroopan unioni - viro - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren, hydrochlorothiazide - hüpertensioon - reniini-angiotensiini süsteemi toimivad ained - essentsiaalse hüpertensiooni ravi täiskasvanutel. sprimeo hct on näidustatud patsientidele, kelle vererõhk ei ole adekvaatselt kontrollitav kohta aliskiren või hydrochlorothiazide kasutada üksi. sprimeo hct on näidustatud asendusravi patsiendid piisavalt kontrollitud aliskiren ja hydrochlorothiazide, arvestades samal ajal, samal annus nagu kombinatsioon.

Viro - viro - Ravimiamet

teva b.v. - amoksitsilliin+klavulaanhape - õhukese polümeerikattega tablett - 875mg+125mg 8tk; 875mg+125mg 4tk; 875mg+125mg 20tk; 875mg+125mg 25tk; 875mg+125mg 15tk; 875mg+125mg 16tk; 875mg+125mg 21tk; 875mg+125mg 12tk; 875mg+125mg 7tk; 875mg+125mg 6tk; 875mg+125mg 30tk; 875mg+125mg 500tk; 875mg+125mg 35tk; 875mg+125mg 100tk

Euroopan unioni - viro - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Euroopan unioni - viro - EMA (European Medicines Agency)

astellas pharma europe b.v. - mirabegron - kusepõiesüst, ülekaakt - uroloogilised ravimid - kiireloomulisuse sümptomaatiline ravi. suurenenud micturition sagedus ja / või kiireloomuline pidamatus, mis võib esineda täiskasvanud patsientidel, kellel on üliaktiivse-põie sündroom.

Euroopan unioni - viro - EMA (European Medicines Agency)

bayer ag - octocog alfa - hemofiilia a. - antihemorraagilised ained - verejooksu ravi ja profülaktika hemofiilia a patsientidel (kaasasündinud viii faktori puudulikkus). iblias võib kasutada kõikides vanuserühmades.

Euroopan unioni - viro - EMA (European Medicines Agency)

bayer ag  - octocog alfa - hemofiilia a. - antihemorraagilised ained - verejooksu ravi ja profülaktika hemofiilia a patsientidel (kaasasündinud faktor viii puudulikkus). see preparaat ei sisalda von willebrand faktori ja ei ole seega näidustatud von willebrand ' s disease.

Euroopan unioni - viro - EMA (European Medicines Agency)

merck europe b.v.  - lutropiin alfa - ovulation induction; infertility, female - suguhormoonid ja genitaalsüsteemi, - luveris koos folliikuleid stimuleeriva hormooni (fsh) preparaadiga on soovitatav folliikulite arengu stimuleerimiseks raske luteiniseeriva hormooni (lh) ja fsh puudulikkusega naistel. kliinilistes uuringutes, need patsiendid olid määratletud on endogeensed seerumi lh tase.

Euroopan unioni - viro - EMA (European Medicines Agency)

ge healthcare as - perflutren - ehhokardiograafia - kontrastsusmeedium - see ravim on mõeldud ainult diagnostiliseks kasutamiseks. optison on transpulmonary echocardiographic kontrastaine kasutamine patsientidel, kellel kahtlustatakse või on kindlaks südame-veresoonkonna haiguste anda matistunud südame kambrid, parandab vasaku vatsakese-endocardial-piiri piiritlemine, mille tulemusena paranenud seina-motion visualiseerimine. optison tuleb kasutada ainult patsientidel, kui uuring ilma kontrastsuse parandamiseks on ebaselge.